ROLE OF METFORMIN IN CORRECTING HYPERINSULINEMIA, MENSTRUAL IRREGULARITY AND ANOVULATION IN POLYCYSTIC OVARY SYNDROME

Authors

  • Shamsa Zafar

Abstract

Background: Previous studies suggest that metformin by reducing hyperinsulinemia is clinicallyuseful in the treatment of polycystic ovary syndrome (PCOS). Our Objective was to observe therole of metformin in correcting oligomenorrhea/amenorrhea and anovulation within six month inhyperinsulinemic women with PCOS. Another aim was to assess the decrease in hyperinsulinemiaand body weight by metformin in our population. Methods: This study was carried out at theDepartment of Obstetrics and Gynaecology, Islamic International Medical Complex (IIMC)Islamabad, from October 2001 to March 2003. Fifty women fulfilling the clinical and biochemicalcriteria for PCOS and hyperinsulinemia were enrolled. Metformin was started at an oral dose of500mg/day and maintained at 1500mg for 6 months. Besides ultrasonography and body weight,serum FSH, LH, fasting insulin, fasting blood sugar and creatinine levels were performed. Aftersix months menstrual cyclicity, fasting insulin levels, day 21 serum progesterone and bodyweights were assessed. Results: After six months of Metformin therapy, menstrual regularity wasachieved in 19 out of 22 women (86%). Out of these 11 women (50%) were ovulating at sixmonths. On Metformin, the median fasting serum insulin decreased from 23.6 micro U/ml to 20.2micro U/ml (P<0.05).There was no significant weight reduction (p=0.096) with Metformin in sixmonths. Data was analyzed using SPSS by paired t-test.Key words; Metformin, PCOS, menstrual irregularity

References

Goudas VT, Dumesic DA. Polycystic ovary syndrome.

Endocrinol Metab Clin North Am. 1997 Dec; 26(4):893-912

Diamanti-Kandarakis E, Zapanti E. Insulin sensitizers and

antiandrogens in the treatment of polycystic ovary syndrome.

Ann N Y Acad Sci 2000; 900:203-12

Wang A, Li M, Lu C. Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by

reduction of insulin secretion. Chung Hua Fu Chan Ko Tsa

Chih 1998 Dec;33(12):731-4

Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L.

Metformin therapy decreases hyperandrogenism and

hyperinsulinemia in women with polycystic ovary syndrome.

Fertil Steril 2000 Jun;73(6):1149-54.

Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L.

Metformin-induced resumption of normal menses in 39 of 43

(91%) previously amenorrheic women with the polycystic

ovary syndrome. Metabolism 1999 Apr;48(4):511-9

Seale FG 4th, Robinson RD, Neal GS. Association of

metformin and pregnancy in the polycystic ovary syndrome.

A report of three cases. J Reprod Med 2000 Jun;45(6):507-10

Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P.

Continuing metformin throughout pregnancy in women with

polycystic ovary syndrome appears to safely reduce firsttrimester spontaneous abortion: a pilot study. Fertil Steril

Jan;75(1):46-52

Wang A, Li M, Lu C.[Role of hyperinsulinemia in

pathogenesis of polycystic ovary syndrome and treatment by

reduction of insulin secretion]. [Article in Chinese].Chung

Hua Fu Chan Ko Tsa Chih 1998 Dec;33(12):731-4

Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L.

Metformin therapy decreases hyperandrogenism and

hyperinsulinemia in women with polycystic ovary syndrome.

Fertil Steril 2000 Jun;73(6):1149-54

Unluhizarci K, Kelestimur F, Sahin Y, Bayram F .The

treatment of insulin resistance does not improve adrenal

cytochrome P450c17alpha enzyme dysregulation in

polycystic ovary syndrome. Eur J Endocrinol 1999

Jan;140(1):56-61

Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo

M, et al. Metformin effects on clinical features, endocrine

and metabolic profiles, and insulin sensitivity in polycystic

ovary syndrome: a randomized, double-blind, placebocontrolled 6-month trial, followed by open, long-term clinical

evaluation. J Clin Endocrinol Metab 2000 Jan;85(1):139-46

Pirwany IR, Yates RW, Cameron IT, Fleming R. Effects of

the insulin sensitizing drug metformin on ovarian function,

follicular growth and ovulation rate in obese women with

oligomenorrhoea. Hum Reprod 1999 Dec;14(12):2963-8

Morin-Papunen LC, Koivunen RM, Tomas C, Ruokonen A,

Martikainen HK. Decreased serum leptin concentrations

during metformin therapy in obese women with polycystic

ovary syndrome. J Clin Endocrinol Metab 1998

Jul;83(7):2566-8

Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ.

Metformin therapy in polycystic ovary syndrome reduces

hyperinsulinemia, insulin resistance, hyperandrogenemia, and

systolic blood pressure, while facilitating normal menses and

pregnancy. Metabolism 1994 May;43(5):647-54

Pasquali R, Gambineri A, Biscotti D. Effect of long-term

treatment with metformin added to hypocaloric diet on body

composition, fat distribution, and androgen and insulin levels

in abdominally obese women with and without the polycystic

ovary syndrome. AM J Clin Endocrinol Metab 2000

Aug;85(8):2767-74

Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A.

Therapeutic effects of metformin on insulin resistance and

hyperandrogenism in polycystic ovary syndrome. Eur J

Endocrinol 1998 Mar;138(3):269-74

Morin-Papunen LC, Koivunen RM, Ruokonen A,

Martikainen HK. Metformin therapy improves the menstrual

pattern with minimal endocrine and metabolic effects in

women with polycystic ovary syndrome. Fertil Steril 1998

Apr;69(4):691-6

Downloads